✦ LIBER ✦

Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil

✍ Scribed by Graham M. Mead; Christopher J. Williams; J. Michael Whitehouse

Publisher: Springer
Year: 1985
Tongue: English
Weight: 163 KB
Volume: 15
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00257534

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined radiotherapy and chemotherapy w

Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study

✍ Mauro G. Trovò; Umberto Tirelli; Antonino De Paoli; Giovanni Franchin; Mario Ron 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 429 KB

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

Randomized trial of initial therapy with

Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878

✍ Scott Wadler; Beow Yeap; Steven Vogl; Paul Carbone 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

## BACKGROUND. Following surgical debulking, most patients with International Federation of Gynecology and Obstetrics (FIGO) Stage 111 or IV carcinoma of the ovary receive treatment with combination chemotherapy. However, the optimal postsurgical therapy for ovarian carcinoma remains to be defined